Journal Guide

The mission of The Journal of Drug Assessment is to provide ethical, unbiased and rapid publication of quality content that is validated by rigorous peer review. The journal’s aim is to serve the information needs of the clinical medicine/research community and of the public to help facilitate improvements in patient health by facilitating a collaborative and honest approach to publication.

• Smaller and lesser-impact studies
• Early trial data
• Incomplete/inconclusive or controversial trial results
• Confirmatory studies
• Updates to previous research
• Full-length “Original Articles” and meta-analyses reporting the results of Phase I–IV studies on pharmaceutical products and medical devices in all drug classes, therapeutic areas and disease states (including approved and unapproved products, therapeutic diagnostic (theranostic) products, and over-the-counter medicines)
• “Brief Research Reports” that meet the above criteria and have the same elements as a full-length paper, but are shorter, and provide more concise information in each element, and fewer illustrations
• Reviews on new and existing drugs, novel study designs, research and pharmacoeconomic outcomes
• Case studies in clinical practice, involving new and existing drugs
• Editorials commenting on new developments in pharmaceutical regulatory affairs, new policies, health outcomes and drug manufacturing, and controversial clinical and preclinical findings
• Letters to the Editor – correspondence to the Editor on previously published work are welcome

READ the journal http://www.sciencedirect.com/science/journal/17732247HERE

The Journal of Drug Delivery Science and Technology is an international journal devoted to drug delivery and pharmaceutical technology. The journal covers all innovative aspects of all pharmaceutical dosage forms and the most advanced research on controlled release, bioavailability and drug absorption, nanomedicines, gene delivery, tissue engineering, etc. Hot topics, related to manufacturing processes and quality control, are also welcomed.

Authoritative, peer-refereed publication affording a wide-ranging coverage of important trends and developments in the drug field. Whatever your area of special interest, the Journal of Drug Education brings timely, helpful information, insights and methodologies that can be adapted to various situations. Look to this Quarterly for critical analyses, innovative approaches, scholarly standards, and clear, concise reports on theoretical, research and programmatic issues.

The Journal of Drug Issues (JDI) was incorporated as a nonprofit entity in the State of Florida in 1971. In 1996, JDI was transferred to the Florida State University College of Criminology and Criminal Justice, and the Richard L. Rachin Endowment was established to support its continued publication. Since its inception, JDI has been dedicated to providing a professional and scholarly forum centered on the national and international problems associated with drugs, especially illicit drugs. It is a refereed publication with international contributors and subscribers. As a leader in its field, JDI is an instrument widely used by research scholars, public policy analysts, and those involved in the day-to-day struggle against the problem of drug abuse.

ournal of Drug Targeting publishes papers and reviews on all aspects of drug delivery and targeting for molecular and macromolecular drugs including the design and characterization of carrier systems (whether colloidal, protein or polymeric) for both vitro and/or in vivo applications of these drugs.Papers are not restricted to drugs delivered by way of a carrier, but also include studies on molecular and macromolecular drugs that are designed to target specific cellular or extra-cellular molecules. As such the journal publishes results on the activity, delivery and targeting of therapeutic peptides/proteins and nucleic acids including genes/plasmid DNA, gene silencing nucleic acids (e.g. small interfering (si)RNA, antisense oligonucleotides, ribozymes, DNAzymes), as well as aptamers, mononucleotides and monoclonal antibodies and their conjugates. The diagnostic application of targeting technologies as well as targeted delivery of diagnostic and imaging agents also fall within the scope of the journal. In addition, papers are sought on self-regulating systems, systems responsive to their environment and to external stimuli and those that can produce programmed, pulsed and otherwise complex delivery patterns.Journal of Drug Targeting also carries papers on the physiological and other biological barriers to delivery and targeting, and means of overcoming the barriers, for example, by penetration enhancers, and covers subjects such as extravasation, diffusion in tumours and target tissues, avoidance of the reticulo-endothelial system, and toxicity testing and licensing of novel delivery systems.The Journal’s life-time achievement award winners to date are: 2009: PP Speiser (Switzerland), 2008: G Gregoriadis (UK), 2007: H Maeda (Japan), 2006: H Ringsdorf (Germany), 2005: A T Florence (UK), 2004: R L Juliano (USA)Read More: http://informahealthcare.com/page/drt/Description.

The Journal of Dual Diagnosis is a quarterly, international publication that focuses on the full spectrum of complexities regarding dual diagnosis. The co-occurrence of mental health and substance use disorders, or 8220;dual diagnosis,8221; is one of the quintessential issues in behavioral health. Why do such high rates of co-occurrence exist? What does it tell us about risk profiles? How do these linked disorders affect people, their families, and the communities in which they live? What are the natural paths to recovery? What specific treatments are most helpful and how can new ones be developed? How can we enhance the implementation of evidence-based practices at clinical, administrative, and policy levels? How can we help clients to learn active recovery skills and adopt needed supports, clinicians to master new interventions, programs to implement effective services, and communities to foster healthy adjustment? The Journal addresses each of these perplexing challenges. The Journal of Dual Diagnosis includes articles and perspectives from four overarching domains relevant to the field: Psychopharmacology & Neurobiology, Psychotherapy & Psychosocial Issues, Services & Policy, and Clinical Forum. Each issue (although not necessarily each article within an issue) serves to encourage integration of these domains. The Journal seeks to publish articles relevant to a wide range of individuals interested in dual diagnosis: researchers; physicians; clinicians; trainees and administrators. High-quality empirical research, brief reports, timely reviews, thought-provoking editorials, and on-going discussions of clinical issues will be considered for publication, all with the aim of developing a better understanding of the basis of and optimal treatment for co-occurring psychiatric and substance use disorders. Publication office: Taylor & Francis, Inc., 325 Chestnut Street, Suite 800, Philadelphia, PA 19106.